Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges.

  title={Enzyme replacement therapy for lysosomal diseases: lessons from 20 years of experience and remaining challenges.},
  author={Robert J. Desnick and Edward H. Schuchman},
  journal={Annual review of genomics and human genetics},
In 1964, Christian de Duve first suggested that enzyme replacement might prove therapeutic for lysosomal storage diseases (LSDs). Early efforts identified the major obstacles, including the inability to produce large quantities of the normal enzymes, the lack of animal models for proof-of-concept studies, and the potentially harmful immune responses to the "foreign" normal enzymes. Subsequently, the identification of receptor-mediated targeting of lysosomal enzymes, the cloning and… 

Treatment of lysosomal storage diseases: recent patents and future strategies.

Recent patents and new strategic approaches for enzyme delivery are discussed to highlight the most relevant aspects, concerning next generation LSDs treatment.

Therapeutic approaches for lysosomal storage diseases: a patent update.

Clinical trials are ongoing based on enzyme enhancement by pharmacological chaperones, small molecule compounds able to increases the residual activity of the lysosomal enzyme, and gene therapy approaches and recent patents in the field provide evidence that many efforts are currently dedicated to improvement of enzymes used for ERT.

Less Is More: Substrate Reduction Therapy for Lysosomal Storage Disorders

The concept of substrate reduction is reviewed, highlighting the major breakthroughs in the field and discussing the future of SRT, not only as a monotherapy but also, especially, as complementary approach for LSDs.

Advancing the Research and Development of Enzyme Replacement Therapies for Lysosomal Storage Diseases.

The opportunity to fill the rare LSD treatment gap with ERTs while gene therapies are in development for these life-shortening diseases is illustrated.

Evolutionary redesign of the lysosomal enzyme arylsulfatase A increases efficacy of enzyme replacement therapy for metachromatic leukodystrophy.

It is shown for human arylsulfatase A (hARSA) that the activity of a therapeutic enzyme can be substantially increased by reversing activity-diminishing and by inserting activity-promoting amino acid substitutions that had occurred in the evolution of hominids and non-human mammals.

JCL Roundtable: enzyme replacement therapy for lipid storage disorders.

Fabry disease: Mechanism and therapeutics strategies

Advances in research on therapeutic approaches, including enzyme replacement therapy (ERT), gene therapy, and chaperone therapy, as well as strategies targeting subcellular compartments, such as lysosomes, the endoplasmic reticulum, and the nucleus are discussed.

Enzyme replacement therapies: what is the best option?

Summary Despite many beneficial outcomes of the conventional enzyme replacement therapy (ERT), several limitations such as the high-cost of the treatment and various inadvertent side effects

Disease models for the development of therapies for lysosomal storage diseases

This paper reviews how LSD patient primary cells and induced pluripotent stem cell–derived cellular models are providing novel assay systems in which phenotypes are more similar to those of the human LSD physiology and larger animal disease models are provide additional tools for evaluation of the efficacy of drug candidates.



Gene therapy for lysosomal storage diseases: progress, challenges and future prospects.

Advances suggesting that the LSDs may be some of the most amenable diseases to treat by gene therapy based approaches are described, however, to overcome the several remaining limitations encountered by these approaches, a deep understanding of the biology ofThe LSDs is required, as well as the host innate and adaptive immune responses to the act of gene transfer.

Combination therapies for lysosomal storage disease: is the whole greater than the sum of its parts?

In order to more successfully treat LSDs, a shift in focus towards a combination therapy may be necessary and a better understanding of both pathogenic and therapeutic mechanisms is necessary in order to identify potentially successful combinations.

Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I.

The results support the conclusion that enzyme replacement is a promising therapy for MPS I though immunologic complications may occur.

Enzyme replacement and enhancement therapies: lessons from lysosomal disorders

This review discusses the successes and shortcomings of these therapeutic strategies, and the contributions that they have made to treating lysosomal storage diseases.

Enhanced response to enzyme replacement therapy in Pompe disease after the induction of immune tolerance.

AAV vector-mediated gene therapy induced a tolerance to introduced GAA, and this strategy could enhance the efficacy of ERT in CRIM-negative patients with Pompe disease and in patients with other lysosomal storage diseases.

New strategies for enzyme replacement therapy for lysosomal storage diseases.

Alternative strategies to deliver the lysosomal enzyme beta-glucuronidase in the enzyme-deficient mucopolysaccharidosis type VII mouse model are investigated, creating an enzyme with increased plasma half-life, resulting in transport across the blood-brain barrier and clearance of storage in neurons.

Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.

Intravenous administration of macrophage-targeted glucocerebrosidase produces objective clinical improvement in patients with type 1 Gaucher's disease.

Status of enzyme replacement therapy for Gaucher disease.

Improve the biochemical and clinical responses to enzyme infusion by investigating the effects of lysosomal modifying agents and by enhancing the uptake and localization of the infused enzyme in lysOSomes of cells that contain the stored glucocerebroside.

Animal models of lysosomal storage diseases: their development and clinical relevance

Inbred strains of a small prolific species, such as the mouse, together with larger out-bred animals, discovered because of their disease phenotype, provide a powerful combination with which to elucidate the pathogenesis of human genetic disease and to investigate approaches to therapy.

Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment

This document summarizes the experience of the professionals involved, along with the data available in the international literature, bringing together and harmonizing the information available on the management of these severe and progressive diseases, thus disclosing new prospects for Brazilian patients affected by these conditions.